Tilray Brands (TLRY) Total Non-Current Liabilities (2019 - 2026)
Tilray Brands (TLRY) reported Total Non-Current Liabilities of $549.0 million for Q1 2026, little changed quarter-over-quarter from $551.7 million in Q4 2025.
Tilray Brands (TLRY) Total Non-Current Liabilities (2019 - 2026) Analysis & Trends
Tilray Brands has reported Total Non-Current Liabilities for 8 years, with the latest figure at $549.0 million in Q1 2026.
- For the quarter ending Q1 2026, Total Non-Current Liabilities changed N/A year-over-year to $549.0 million; the trailing twelve-month figure through Feb 2026 stood at $549.0 million (changed N/A YoY), and the FY2025 full-year result was $583.9 million, down 24.99% from the prior year.
- Total Non-Current Liabilities for Q1 2026 stood at $549.0 million, roughly flat from $551.7 million in the prior quarter.
- The five-year high for Total Non-Current Liabilities was $1.2 billion in Q1 2022, with the low at $549.0 million in Q1 2026.
- Historically, Total Non-Current Liabilities has averaged $841.7 million across 5 years, with a median of $903.4 million in 2023.
- Annual changes were most pronounced in 2022 — Total Non-Current Liabilities tumbled 35.52% — and 2023, when it decreased 2.77%.
- Tilray Brands' Total Non-Current Liabilities stood at $991.0 million in 2022, then fell by 5.43% to $937.2 million in 2023, then slipped by 21.24% to $738.1 million in 2024, then declined by 25.26% to $551.7 million in 2025, then fell by 0.49% to $549.0 million in 2026.
- The last three Total Non-Current Liabilities figures came in at $549.0 million (Q1 2026), $551.7 million (Q4 2025), and $562.0 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 38.34 Bn | 34.60 Bn | 1.97 Bn | 18.28 Bn |
| 2 | Zoetis | 33.27 Bn | 31.33 Bn | 1.62 Bn | 11.64 Bn |
| 3 | United Therapeutics | 23.75 Bn | 21.60 Bn | 648.10 Mn | 599.10 Mn |
| 4 | Aurora Cannabis | 17.11 Bn | 17.03 Bn | 33.43 Mn | 44.12 Mn |
| 5 | Neurocrine Biosciences | 16.37 Bn | 15.05 Bn | 800.70 Mn | 1.24 Bn |
| 6 | Elanco Animal Health | 11.78 Bn | 11.35 Bn | 785.00 Mn | 6.26 Bn |
| 7 | Alkermes | 7.05 Bn | 6.54 Bn | -116.06 Mn | 2.44 Bn |
| 8 | Lantheus Holdings | 6.49 Bn | 5.99 Bn | 230.92 Mn | 1.13 Bn |
| 9 | Hims & Hers Health | 6.19 Bn | 5.44 Bn | 396.79 Mn | 1.81 Bn |
| 10 | Tilray Brands | - | - | 54.95 Mn | 548.95 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Feb 28, 2026 | 548.95 Mn |
| Nov 30, 2025 | 551.67 Mn |
| Aug 31, 2025 | 561.99 Mn |
| May 31, 2025 | 583.90 Mn |
| Nov 30, 2024 | 738.13 Mn |
| Aug 31, 2024 | 778.35 Mn |
| May 31, 2024 | 778.40 Mn |
| Feb 29, 2024 | 869.61 Mn |
| Nov 30, 2023 | 937.20 Mn |
| Aug 31, 2023 | 1.00 Bn |
| May 31, 2023 | 966.43 Mn |
| Feb 28, 2023 | 965.79 Mn |
| Nov 30, 2022 | 991.05 Mn |
| Aug 31, 2022 | 1.03 Bn |
| May 31, 2022 | 1.01 Bn |
| Feb 28, 2022 | 1.16 Bn |
| Nov 30, 2021 | 1.29 Bn |
| Aug 31, 2021 | 1.60 Bn |
| May 31, 2021 | 1.56 Bn |
| Mar 31, 2020 | 719.84 Mn |